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Abstract
  . X  . .The antitumor sulfonylurea LY237868 N- 4-aminophenyl-sulfonyl -N - 4-chlorophenyl urea was conjugated through
 .the A ring to a-cyclodextrin or agarose bead material Affigel 10 to prepare impermeant conjugates for activity
measurements and affinity isolation of binding proteins from serum. When conjugated to a-cyclodextrin, the resulting
LY237868 conjugate inhibited both NADH oxidase activity and growth of HeLa cells in culture. The conjugate was at least
one order of magnitude more potent as an inhibitor than the parent compound. These findings confirm previous results that
demonstrate an antitumor sulfonylurea-binding protein with NADH oxidase activity at the external plasma membrane
surface of HeLa cells that is shed into culture media conditioned by growth of HeLa cells. A comparable activity,
responsive to sulfonylurea, was present in sera of cancer patients. LY237868 conjugated to agarose beads as the affinity
support bound a large number of serum proteins. However, compared to serum from normal patients, the affinity support
bound two proteins of M approx. 33.5 and 29.5 not found in sera of normal patients. The 33.5 kDa protein from humanr
sera reacted with antisera to a 33.5 kDa protein from culture media conditioned by growth of HeLa cells that blocked and
immunoprecipitated the sulfonylurea-responsive activity from HeLa cell plasma membranes. The results point to the 33.5
kDa protein from cancer patient sera that bound to the sulfonylurea affinity support as representing the circulating
equivalent of the previously identified 34 kDa sulfonylurea-binding protein, with NADH oxidase activity at the external cell
surface of cultured HeLa cells and a corresponding 33.5 kDa protein shed into culture media conditioned by growth of
HeLa cells.
Keywords: Diarylsulfonylurea; Sulfonylurea; Antitumor drug; Drug conjugate; Cyclodextrin; HeLa
 . XAbbreviations: LY181984, N- 4-methylphenylsulfonyl -N -
 .  . Xchlorophenyl urea; LY237868, N- 4-aminophenylsulfonyl -N -
 .4-chlorophenyl urea; a-CD, a-cyclodextrin; DMSO, dimethyl-
sulfoxide
)  .Corresponding author. Fax: q1 317 494 4007; e-mail:
crawmore@pharmacy.purdue.edu.
1. Introduction
Previous findings from our laboratories have de-
 .scribed a high affinity K s30 nM sulfonylurea-d
binding activity of HeLa cells associated exclusively
w xwith the plasma membrane 1 . The binding activity
was tentatively identified as a 34 kDa binding protein
w x2 with NADH oxidase activity inhibited by antitu-
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w xmor sulfonylurea 3 . The antitumor sulfonylurea-in-
hibited activity was associated with an NADH site at
w xthe external plasma membrane surface 4 , and a
comparable activity tentatively identified as a 33.5
kDa soluble form of the activity was identified from
culture media conditioned by growth of HeLa cells
w x5 . An antitumor-responsive NADH oxidase activity
subsequently was demonstrated in sera of cancer
w x patients 6 . These studies were with N- 4-methyl-
. X  .phenylsulfonyl -N - 4-chlorophenyl urea designated
LY181984. The present study was with a similar
 com pound designated LY 237868 N - 4-
. X  . .aminophenylsulfonyl -N - 4-chlorophenyl urea with
w xantitumor activity 7 that could be readily conjugated
to impermeant or affinity supports. The findings pro-
vide additional evidence using HeLa cells and plasma
membranes isolated from HeLa cells for an external
sulfonylurea-binding site at the HeLa cell plasma
membrane surface. Additionally, when bound to an
affinity support, the conjugated LY237868 bound two
constituents of M 33.5 and 29.5 kDa from sera ofr
cancer patients not found in sera of normal individu-
als.
2. Materials and methods
2.1. Growth of cells
HeLa S cells were grown on Minimal Essential
 .  .Medium S-MEM Jolik modified with glutamine
 .  .244 mgrl and phosphate 1.3 grl Na HPO and2 4
without CaCl plus 5% donor horse serum. Gen-2
 . tamycin sulfate 50 grl and sodium bicarbonate 2
.grl were added.
 .Attached HeLa cells ATCC CCL2 , were grown
in 150-cm flasks in Minimal Essential Medium
 .  .Gibco pH 7 , at 378C with 10% bovine calf serum
 .heat-inactivated , plus 50 mgrl gentamycin sulfate
 .Sigma . Cells were trypsinized with Sigma IX trypsin
for 1 to 2 min and harvested by scraping and taken
up in TD-Tris buffer 140 mM NaCl, 5 mM KCl, 0.7
 ..mM Na HPO and 25 mM Tris pH 7.4 to a final2 4
 .cell concentration of 0.1 g wet weight gww per ml.
Cell survival was determined by Eosin Y exclusion.
2.2. Growth measurements
Attached HeLa cells were treated in 35=10 mm
plastic dishes in 2.5 ml culture medium. Sulfonyl-
ureas were dissolved in DMSO and added in 2.5 ml
of DMSO to yield a final DMSO concentration of
0.1%. Controls received 2.5 ml of DMSO. Growth
inhibitions were determined from cell numbers esti-
mated after 24, 48, 72 and 96 h of treatment.
2.3. Purification of plasma membranes from HeLa
cells
HeLa cells grown as suspension cultures were
collected by centrifugation for 6 min at 3000 rpm or
15 min at 1000 rpm. The cell pellets were resus-
pended in 0.2 mM EDTA in 1 mM NaHCO in an3
approximate ratio of 1 ml per 108 cells and incubated
on ice for 10 to 30 min to swell the cells. Homoge-
nization was with a Polytron homogenizer for 30 to
40 s at 10 500 rpm using a PT-PA 3012r23 or
ST-probe and 7–8 ml aliquots. To estimate breakage,
the cells were monitored by light microscopy before
and after homogenization. At least 90% cell breakage
without breakage of nuclei was achieved routinely.
The homogenates were centrifuged for 10 min at
 .1000 rpm 175 g to remove unbroken cells and
nuclei and the supernatant was centrifuged a second
6  .time at 1.4P10 g min e.g. 1 h at 23 500=g to
prepare a plasma membrane enriched microsome
fraction. The supernatant was discarded and the pel-
lets were resuspended in 0.2 M potassium phosphate
buffer in a ratio of approximately 1 ml per pellet
from 5P108 cells. The resuspended membranes are
then loaded onto the two-phase system constituted on
w xa weight basis as described 8 . The upper phase,
enriched in plasma membranes, was diluted 5-fold
with 1 mM sodium bicarbonate and the membranes
were collected by centrifugation. The purity of the
plasma membrane was determined to be )90% by
w xelectron microscope morphometry 8 . The yield was
20 mg plasma membrane protein from 1010 cells.
2.4. Spectrophotometric assay of NADH oxidase ac-
ti˝ity
NADH oxidase activity was determined as the
disappearance of NADH measured at 340 nm in a
reaction mix containing 25 mM Tris-MES buffer pH
.7.2 , 1 mM KCN to inhibit any potential mitochon-
drial oxidase activity, and 150 mM NADH at 378C
with constant stirring. Activity was measured using a
Hitachi U3210 with continuous recording over 5–10-
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min intervals. A millimolar extinction coefficient of
6.22 was used to calculate NADH disappearance.
2.5. Conjugation of LY237868 with a-cyclodextrin
( )a-CD
The overall conjugation strategy of LY237868 with
a-CD is shown in Fig. 1.
2.5.1. Reaction of a-CD with succinic anhydride
a-CD was dried at 1058C overnight. From the dry
 .a-CD, 2.7 g of a-CD 2.8 mol was dissolved in 50
 .ml of pyridine dried over NaOH . To this solution,
 .25 g of succinic anhydride 250 mmol in 30 ml of
pyridine was added. The reaction was heated
overnight at 808C with stirring. After reaction, 50 ml
distilled water was added and the insoluble residue
was washed with excess dichloromethane and dried
under vacuum. Persuccinylated a-CD 5.07 g, 2.2
.mmol, m.p.s125–1308C uncorrected was purified
by reversed-phase chromatography Sephasil C18,
.2.5=18 cm, Pharmacia Biotech with a solvent sys-
tem composed of 5% methanol in dichloromethane.
The R of the product on silica gel TLC was 0.28f
while that of the a-CD was 0.54 n-
.butanolrethanolrwaters4:3:2 . The degree of suc-
cinylation of the a-CD was 14.1 as determined by
plasma desorption mass spectrometry.
2.5.2. Conjugation of persuccinylated a-CD with
LY237868
For conjugation of the persuccinylated a-CD with
LY237868, 0.14 g persuccinylated a-CD 0.059
.  .mmol and 0.29 g of LY237868 0.90 mmol were
dissolved in 20 ml of dry pyridine. To this solution,
 .0.26 g of 1-ethyl-3- 3-dimethylaminopropyl carbo-
 .  .diimide EDAC 1.36 mmol was added. The reac-
tion was stirred overnight at 258C. The a-CD-
LY237868 conjugate 0.24 g, 0.036 mmol, m.p. 194–
.196, uncorrected was purified by precipitation with
ethyl acetate. The product expected average molecu-
.lar mass of 6723 was immobile on silica gel TLC.
Neither FAB mass spectrometry nor plasma desorp-
tion mass spectrometry was useful in the analysis of
the molecular mass of the conjugate. Formation of
the conjugate was confirmed by 1H-NMR spectrome-
try and FT-IR spectrometry Section 2.11 and Section
.2.12 .
 .Fig. 1. Scheme showing the overall strategy of conjugation of LY237868 with a-cyclodextrin a-CD .
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2.6. Synthesis of sulfonylurea–acetic acid conjugate
 .Acetic acid N-hydroxy succinimide ester 0.037 g
 .  .  .0.23 mmol and LY237868 0.045 g 0.14 mmol
were dissolved in 2 ml of dry methanol dried over
.molecular sieve . The reaction was for 5 h at room
temperature with stirring. The conjugate was purified
by silica gel chromatography 50 ml bed volume,
.Ia trobeads, Ia tron L abora to ries , Japan
 .MeOHrCH Cl s10:1 . Fractions containing the2 2
 .conjugate 26 mg, 0.07 mmol, R values0.79 weref
pooled and dried.
2.7. Preparation of sulfonylurea affinity support
For preparation of the affinity support, 0.5 g of
 .LY237868 1.5 mmol was dissolved in methanol. To
 .this solution, 5.0 ml of Affigel 10 resin BioRad in
methanol suspension was added. The reaction was for
5 h at room temperature with stirring and the remain-
ing reactive groups of the resin were blocked by
excess ethyl amine for an additional 2 h. The resin
was washed with methanol and then 20 mM Tris-HCl
 .pH 7.2 , containing 5% methanol and used directly
as the sulfonylurea affinity support.
2.8. Affinity purification of serum proteins
For affinity purification, pooled sera from cancer
 .patients breast, prostate, lung, colon, ovarian, etc.
or from normal individuals was loaded on the affinity
support in the presence of 1 mM reduced glutathione.
Elution was with increasing concentrations of the
active antitumor sulfonylurea N- 4-methylphenyl-
. X .  .sulfonyl -N phenyl urea LY181984 of 1, 10 and
100rmM prepared in 20 mM Tris-HCl, pH 7.2,
containing 5% methanol. Eluted proteins were ana-
 .lyzed by SDS-PAGE 9.5% with detection using
w xsilver staining 9 .
2.9. Western blot analysis of immunoprecipitates with
antisera to a 33.5 kDa protein with sulfonylurea-in-
hibited NADH oxidase acti˝ity from culture media
conditioned by growth of HeLa cells
For immunoprecipitation, NP-40 at a final concen-
tration of 0.1% was added to 100 ml of conditioned,
defined culture medium from HeLa cells or 100 mg
HeLa S plasma membranes. Protein A Sepharose
 .  .PAS was added 3.6 mg in 50 ml and the mixture
was incubated at 48C for 4 h with shaking. The PAS
Fig. 2. Plasma desorption mass spectrum of persuccinylated a-cyclodextrin. The degree of substitution is designated by n.
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 .was removed by centrifugation Microfuge, 1 min
and 2.5 ml of antisera or preimmune sera were added
and incubated overnight at 48C with shaking. PAS
again was added and the mixture incubated for 2 h.
The PAS was collected by centrifugation and the
supernatant assayed for NADH oxidase activity. The
pellets were washed twice with 0.1% ND-40 and
once each with PBS and water and analyzed by 10%
PAGE and Western blot.
For Western blot analysis, immunoprecipitates
from sera were separated on 10% SDS-PAGE and
then transferred by electroblotting onto nitrocellulose.
To block unspecific antibody binding sites, the blot
was placed in a solution of 1% bovine serum albu-
min, 10 mM Tris-HCl, 150 mM NaCl and 0.1%
 .Tween-20 TBS-T for 15 min. The blot was placed
 .in the primary antibody solution 1:1000 in TBS-T
overnight at 48C with shaking. The blots were washed
with TBS-T four times for 15 min each after which
the blots were placed into secondary antibody solu-
tion Goat anti-rabbit linked to alkaline phosphatase,
Jackson ImmunoResearch Laboratories, West Grove,
.PA, 1:25,000 in TBS-T for 30 min at room tempera-
ture with shaking. The blot was washed with TBS-T
three times for 15 min each and placed in a mixture
of 0.33rmgrml nitro blue tetrazolium and 0.16
mgrml of 5-bromo-1-chloro-3-indolyl phosphate pre-
 .pared in 100 mM Tris pH 9.5 , containing 100 mM
NaCl and 5 mM MgCl and incubated with shaking2
until the purple color of positive bands appeared. The
color development reaction was stopped by placing
 .the blots in 20 mM Tris pH 8 , containing 5 mM
EDTA.
2.10. Plasma desorption mass spectrometry
The plasma desorption mass spectra were obtained
with a Bioion 20R mass spectrometer Uppsala, Swe-
.den . Samples were applied to a nitrocellulose-coated
mylar target and data were collected at an accelerat-
ing voltage of 17 kV.
2.11. 1H-NMR spectrometry
1H-NMR spectra were recorded at 208C on a
Varian VXR-500 spectrometer operating at 500 MHz.
All compounds were dissolved in DMSO-d and 1H6
chemical shifts were referenced to DMSO-d 2.586
.ppm .
( )2.12. Fourier transform-infrared FT-IR spectrome-
try
IR spectra were obtained with a Perkin-Elmer
Model 1600 FT-IR spectrometer with 16 kilobytes of
1  .  .Fig. 3. H-NMR spectra. A a-Cyclodextrin. B Persucciny-
 .lated a-cyclodextrin. C a-Cyclodextrin conjugated to
LY237868. Each compound was dissolved in DMSO-d and6
1H-NMR spectra were recorded at 500 MHz.
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battery-backed memory, software with extensive
graphics and data processing capability based on
Perkin-Elmer’s CD-3 infrared data system. Samples
for IR spectral analysis were prepared by the KBr
disc method at room temperature. Spectra were ob-
tained from 4000 to 600 cmy1.
3. Results
To test the concept that the NADH oxidase inhib-
ited by sulfonylurea was accessible to NADH sup-
plied from the external surface, we utilized an imper-
meant conjugate of an LY181984 analog substituted
with an amino group in position 3 of the A ring
 .LY237868 . This amino group was then used to link
the sulfonylurea to an impermeant cyclodextrin.
Persuccinylated a-CD was identified by plasma
 . 1desorption mass spectrometry Fig. 2 and H-NMR
 .spectrometry Fig. 3B . Degree of substitution of
a-CD by succinyl groups was 14.1 as determined
Fig. 5. Inhibition of NADH oxidase of sealed right-side-out
vesicles of HeLa plasma membrane by the a-cyclodextrin conju-
gate of LY237868 as a function of concentration compared to the
unconjugated LY237868. Both were inhibitory.
Fig. 6. Cytotoxicity of the a-cyclodextrin conjugate of LY237868
at two concentrations compared to a-cyclodextrin and LY181984
or LY237868 based on growth over 72 h of attached HeLa cells.
The O is for the DMSO control. All drugs were dissolved in
DMSO. Results are averages of three experiments"standard
deviations among experiments.
from the intensity of the major peaks of the plasma
desorption mass spectrum.
The molecular mass of the a-CD conjugated to
LY237868 could not be obtained by plasma desorp-
tion mass spectrometry, due to the high expected
average molecular mass of 6723. However, its cross-
1 linking was verified by H-NMR spectrometry Fig.
.3C and its immobility upon silica gel thin layer
chromatography.
Cross-linking also was verified from the infrared
 .spectra Fig. 4 that showed the disappearance of
N–H stretching vibrations of the primary amino group
 .of LY237868 arrows in Fig. 4B in a CD-LY237868
 .conjugate Fig. 4D , and its replacement by an amide
bond as shown by C-O stretching vibrations at
y1  .1725.5 cm arrow in Fig. 4D .
On a sulfonylurea basis, the cross linked com-
pound was as active or even more active than the
parent compound in inhibiting the NADH oxidase of
 .HeLa plasma membranes Fig. 5 . Inhibition by 50%
of the activity was observed at a conjugate concentra-
tion equivalent to 1 nM LY237868. When tested for
inhibition of growth of HeLa cells, the conjugate was
considerably more inhibitory than the parent com-
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 .pound Fig. 6 and even more active than the active
cancer sulfonylurea LY181984. a-Cyclodextrin by
itself was without effect.
In subsequent experiments, the LY237868 was
 .conjugated to agarose beads Affigel 10, BioRad as
an affinity support. In a model study, we have linked
LY237868 to acetic acid N-hydroxysuccinimide ester
using the same active ester chemistry as used in
preparing sulfonylurea affinity support. In this proce-
dure, acetic acid N-hydroxysuccinimide ester was
linked to the LY237868 to form the 4X-acylamine
derivative. The product was conclusively identified
by determining its exact mass by mass spectrometry:
Found, 367.03767; Calcd., 367.03936 for
C H N O SCl.15 14 3 4
To test the affinity support, sera pooled from
cancer patients was passed over the column. Elution
of bound proteins was with the active antitumor
sulfonylurea LY181984 in DMSO. A number of pro-
Fig. 7. Proteins eluting from a sulfonylurea affinity column
 .which binds albumin among a variety of other serum proteins
with 1 mM LY181984. Of interest was a band at about 33.5 kDa
 .in sera from cancer patients small arrow not found in sera of
normal individuals. Also seen was a band at about 29.5 kDa
 .large arrow also found in sera from cancer patients and not
found in sera of normal individuals. A band at 36 kDa was found
in both normal and cancer but was more prominent in sera of
 .normal individuals double arrows .
Fig. 8. Western blot of immunoprecipitates. Rabbit polyclonal
antisera to tNOX isolated from culture media conditioned by
 .growth of HeLa cells AB were used for detection. Lanes were
loaded with immunoprecipitates from 50 ml of pooled sera from
 .  .normal individuals N or pooled sera of cancer patients C . The
 .two lanes on the left were reacted with preimmune sera PI . The
 .two lanes on the right were reacted with antisera AB . The
antisera reacted specifically with a 33.5 kDa component
 .arrowhead obvious only with the pooled sera from cancer
patients. The small arrow indicates the position of the 29.5 kDa
 .component as part of a poorly resolved doublet double arrows
partly obscured by material present in both sera of cancer patients
and of normal volunteers and reactive as well with the preim-
 .mune sera single arrows .
teins, including serum albumin, bound to the column.
However, comparing pooled sera from cancer pa-
tients to pooled sera from normal individuals several
 .important differences were noted Fig. 7 . Bands with
 .a M of 33.5 and 29.5 29–30.5 kDa, respectively,r
were eluted from the affinity support with 1 mM
LY181984 with pooled sera from cancer patients and
were absent with sera pooled from normal individu-
als. A protein band at 36 kDa was somewhat more
evident with sera pooled from normal individuals
than from pooled cancer sera. In other respects the
two gel profiles were identical.
Since the NADH oxidase activity of the drug-re-
sponsive form was completely inhibited by 0.1 mM
sulfonylurea, it was not possible to assay sulfonyl-
urea-inhibited NADH oxidase activity with the eluted
fractions. Additionally, the components unique to
cancer serum were still minor components of the
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mixture of proteins bound to the affinity support.
That the sulfonylurea-inhibited NADH oxidase activ-
ity did bind to the affinity column was confirmed by
a failure of the activity to appear in the column
flow-through. Activity could be partly restored by
adding excess human serum albumin to bind the
excess sulfonylurea followed by overnight dialysis.
The protein band with a M of 33.5 kDa andr
specific to the pooled sera of cancer patients, how-
ever, was reactive with polyclonal antisera prepared
to a comparable 33.5 kDa protein shed from HeLa
cells into culture media conditioned by growth of
 .HeLa cells arrowhead, Fig. 8 . Whether or not the
29.5 kDa band from the sulfonylurea affinity column
was related to the NADH oxidase could not be
determined. On the immunoblots the cancer-specific
 .band at 29.5 29–30.5 kDa may have been present
as the upper band of a poorly resolved doublet small
.arrows, Fig. 8 . The f29.5 kDa band was largely
obscured by reactivity with material present in both
normal and cancer sera but also reactive with the
 .preimmune sera single arrows, Fig. 8 .
The polyclonal antisera from HeLa that cross-re-
acted with the 33.5 kDa material retained by the
sulfonylurea affinity column and eluted with 1 mM
LY181984 specifically inhibited as well as immuno-
precipitated the drug-responsive NADH oxidase ac-
tivity of HeLa plasma membranes and the corre-
sponding drug-responsive NADH oxidase activity
shed by HeLa cells into media conditioned by the
w xgrowth of HeLa cells 5 . Preimmune sera or sera to
 . antigens other than the 34 33.5 kDa protein e.g.
.antiserum albumin did not inhibit the activity. The
polyclonal antisera also inhibited the drug-responsive
NADH oxidase activity of pooled sera from cancer
patients and was without effect on sera pooled from
healthy volunteers or from patients with disorders
other than cancer. On Western blots, immunoreactiv-
ity of the 33.5 kDa component from sera of cancer
patients was not given by preimmune sera nor by
secondary antisera alone.
4. Discussion
The chloroaniline structure of the A ring of the
antitumor sulfonylureas was critical to activity in the
w xinhibition of xenograft growth 7 . The structure of
the B ring was less critical. The 4-aminophenyl B
ring gave rise to an active antitumor sulfonylurea and
afforded an opportunity to immobilize the sulfonyl-
urea to an impermeant support.
Since a-cyclodextrin has six primary hydroxyl and
twelve secondary hydroxyl groups, it was an attrac-
tive candidate for drug conjugation. Succinic anhy-
dride provided a four carbon linker between the
a-cyclodextrin and the LY237868. The degree of
substitution of a-cyclodextrin by succinyl groups
was 14.1 and this high degree of substitution led to
an effective conjugation.
When attached to a-cyclodextrin, the sulfonylurea
LY237868 not only retained activity but the conju-
gates appeared to be more active than the parent
sulfonylurea. The conjugates effectively blocked the
w xNADH oxidase of right-side-out 4 plasma mem-
brane vesicles. Since the a-cyclodextrin–LY237868
conjugate would be unlikely to penetrate the isolated
and sealed plasma membrane vesicle, these results
w xsupport previous findings 4 that the antitumor sul-
fonylurea-inhibited site of NADH oxidation was at
the external cell surface.
The possibility of an external NADH oxidase in
HeLa cells was first raised by studies with sealed
plasma membrane vesicles of known absolute orien-
w xtation 4 . Membrane integrity of the isolated vesicles
after treatment with sulfonylureas or with the sul-
fonylurea–a-cyclodextrin conjugate was verified us-
ing electron microscopy. After repeated freezing and
thawing, some of the vesicles were everted so that
populations of both right-side-out and inside-out were
present. The right-side-out vesicles exhibited an elec-
trophoretic mobility greater than that of the inside-out
vesicles. Sidedness was confirmed by measurements
of ATPase latency and binding of immunogold-
labeled concanavalin A. When the two vesicle popu-
lations were resolved by preparative free-flow elec-
trophoresis, the active antitumor sulfonylurea
LY181984 inhibited only the NADH oxidase activity
of the right-side-out vesicles. These findings sug-
gested two NADH sites or activity forms for the
plasma membrane NADH oxidase. One activity, in-
hibited by LY181984, appeared to be accessible to
 .external NADH an impermeant substrate only with
sealed right side-out vesicles. The other, not inhibited
by LY181984, was accessible to NADH with sealed
inside-out vesicles. After membrane disruption by
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Triton X-100, both NADH oxidase forms were acces-
sible to NADH. The findings demonstrate that the
NADH oxidation site inhibited as a result of binding
the active antitumor sulfonylurea LY181984 was at
the external cell surface. Plasma membrane vesicles
from HeLa cells were able to oxidize NADH sup-
plied to either membrane surface, but only with
right-side-out vesicles was NADH oxidation sensitive
to inhibition by the antitumor sulfonylurea.
It is unlikely, however, that an ectoenzyme which
requires as much as 0.15 mM NADH as an extracel-
lular substrate could function physiologically as an
NADH oxidase. Therefore, the physiological electron
acceptor for the sulfonylurea-inhibited NADH oxi-
dase has been assumed to be some constituent en-
dogenous to the plasma membrane rather than NADH,
since an extracellular source of NADH in the body
would be highly unlikely. Protein thiols and disul-
fides were indicated as the physiological substrates
for the activity rather than NADH. In the presence of
NADH there was an increase in protein disulfides
and a corresponding decrease in membrane thiols
both of which were inhibited by 1 mM LY181984
w x10 . In the absence of NADH, the protein appears to
function as a protein disulfide-thiol interchange activ-
w xity 11 . This latter activity also was inhibited by the
w xactive antitumor sulfonylureas 11 .
In support of the above hypothesis as well as in
support of an external form of the NADH oxidase
were results with the impermeant thiol reagent 5,5X-
 .  .dithiobis 2-nitrophenylbenzoate DTNB . DTNB in-
hibited specifically the NADH oxidase activity of
HeLa cells and was without effect on the correspond-
ing activity of plasma membrane vesicles prepared
w xfrom rat liver 12 .
The inhibition of growth of HeLa cells by the
a-cyclodextrin-LY237868 conjugate also would sup-
port the conclusion that the principal site of antitumor
activity of the sulfonylureas was at the external cell
surface. In contrast to plasma membrane vesicles, we
did not exclude endocytic uptake of conjugate or
release of free drug with HeLa cells. However, since
the LY237868-a-cyclodextrin conjugate, on a sul-
fonylurea basis, was even more effective than free
LY237868 or even the more active LY181984, such
explanations to account for the conjugate activity
seem less likely. If the drug site for the sulfonylureas
was indeed at the external surface of the cells, the
conjugate might be expected to be more active on a
molar sulfonylurea basis. The sulfonylurea was lipid
soluble and would be able to enter and cross the
membrane. By restricting the drug to the cell surface,
it appeared that overall effectiveness was increased
perhaps by as much as one order of magnitude.
The concept of a cell surface site of action for
anticancer drugs is not new. Inhibition of cell growth
by adriamycin and other anthracyclines covalently
linked to polymers to prevent entrance into cells was
w xdemonstrated earlier by Tritton and Yee 13 and
w xTokes et al. 14 . Growth inhibition was observed¨
when the adriamycin was attached to agarose beads
w x w x13 , polyvinyl alcohol 15 , polyglutaraldehyde mi-
w x  .crospheres 14,16 , N- 2-hydroxypropyl methacryl-
w x w xamide 17 or diferric transferrin 18 . It was con-
cluded from these studies that the anthracyclines
disrupt cellular growth processes without actually
 w x.entering cells see also Ref. 19 . As with the sul-
fonylurea-a-cyclodextrin conjugate reported here, the
anthracycline conjugates often were more effective
than was the free drug on a per mole of drug basis.
With adriamycin attached to agarose, immobilized
adriamycin was 100- to 1000-times more active than
w xwas free adriamycin 13 . With adriamycin bound to
w xthe polyglutaraldehyde microspheres 14,16,19 , in-
creased effectiveness on an adriamycin basis also was
found. Transferrin–adriamycin conjugates also have
proven to be disproportionately more effective than
w xfree adriamycin 20 . The latter were tested clinically
and found to be therapeutic in the treatment of
w xleukemia 21,22 .
Since the LY237868-a-cyclodextrin complex did
appear to interact with the NADH oxidase, the
LY237868 was attached to an agarose affinity sup-
port. As a source of starting material, serum from
cancer patients and from normal individuals were
compared. Sera from cancer patients, but not that
from normal individuals, contained a NADH oxidase
activity either stimulated or inhibited by the antitu-
mor sulfonylurea LY181984, a sulfonylurea closely
related chemically to LY237868. The inhibitions
ranged from 10% to 50% and were given by sera
over a wide range of tumor types including both solid
w xand cellular cancers 6 .
When applied to the affinity column with elution
by 1 mM LY181984, two protein bands of apparent
molecular masses of 33.5 and 29.5 kDa not present
( )C. Kim et al.rBiochimica et Biophysica Acta 1324 1997 171–181 181
with pooled sera of normal individuals were observed
with sera of cancer patients. The 33.5 kDa compo-
nent corresponded to a comparable protein shed into
culture media conditioned by growth of HeLa cells
w x5 . Polyclonal antisera raised to the 33.5 kDa compo-
nent from the conditioned media, reacted with a 33.5
kDa component from cancer sera. No 33.5 kDa im-
munoreactive protein was observed with sera from
normal individuals. The nature of protein in the
 .vicinity of 29.5 29–30.5 kDa associated with the
pooled sera from cancer patients and eluted with 1
mM sulfonylurea remains problematic. Although ap-
parently present on the immunoblots as the upper
band of a poorly resolved doublet, it was largely
obscured by material also reactive with preimmune
sera and present in sera from both cancer patients and
healthy volunteers. Despite the latter difficulty and
the fact that the affinity support bound a mixture of
several proteins that were eluted with sulfonylurea,
two proteins were identified as being unique to sera
of cancer patients. One of these, with a M of 33.5,r
corresponded to the shed form of the sulfonylurea-
binding protein previously identified from culture
media conditioned by growth of HeLa cells. This
component, and possibly the 29–30.5 kDa compo-
nent as well, may provide one or more targets suit-
able for exploitation as cancer markers with potential
utility in the development of new diagnostic and
therapeutic strategies.
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